Neuroscience & Neurodegeneration
From Alzheimer's plaques to MS-related demyelination, Krishgen offers a comprehensive portfolio of validated ELISA kits for neurological biomarkers, neurotrophic factors, and mAb drug monitoring — across 10+ species and all major neurodegenerative disease models.
Six dimensions of neuroscience research
Krishgen's neuroscience portfolio is organised around the biological processes and pathologies most active in current research — from amyloid clearance to glial activation and therapeutic drug monitoring.
Priority ELISA targets in neurodegeneration research
These core biomarkers are the most widely measured in CSF, plasma, and brain tissue across Alzheimer's, Parkinson's, and broader neurodegeneration studies. All are available in Human, Mouse, and Rat formats, with several extended to 10+ additional species.
Matched Human, Mouse & Rat kits — same assay architecture
Cross-species consistency matters in neurodegeneration. When you transition from a mouse model of tauopathy to human CSF samples, you want the same sandwich format, detection antibody class, and standard curve range — not a new assay to validate. Krishgen supplies matched species kits with consistent design across the neurodegenerative biomarker range, reducing cross-species method development time.
Every kit is validated for sensitivity, specificity, intra-assay precision (<8% CV), inter-assay precision (<10% CV), accuracy, and lot-to-lot consistency. For extended species, Rabbit, Porcine, Bovine, Equine, Canine, Goat, Sheep, Chicken, and Primate formats are available on request for BDNF, Tau, and Amyloid markers.
ELISA for approved & emerging neuro mAb therapeutics
Monoclonal antibody drugs for neurological diseases target misfolded protein aggregates (Aβ, α-synuclein), immune cell surface antigens (CD20, CD52), and cell adhesion molecules (α4-integrin). Krishgen provides both the drug PK ELISA and the corresponding target biomarker ELISA — enabling complete monitoring of drug exposure and target engagement in a single vendor relationship.
```Anti-Amyloid mAb Drugs — Alzheimer's Disease
Both currently approved anti-amyloid mAbs — Aducanumab (Aduhelm) and Lecanemab (Leqembi) — target aggregated beta-amyloid fibrils and protofibrils respectively. As the first disease-modifying therapies for Alzheimer's disease, they have created a significant need for validated assays to measure drug PK, immunogenicity, and target engagement (Aβ40 and Aβ42 levels as PD biomarkers). The Amyloid Beta 40 and Amyloid Beta 42 ELISA (Human, Mouse, Rat) are available now; drug-specific PK ELISA are in development.
| Drug (Brand) | Target | Indication | Drug PK ELISA | Target ELISA (Human) | Target ELISA (Mouse/Rat) |
|---|---|---|---|---|---|
Aducanumab Aduhelm • Biogen |
Beta-Amyloid (aggregated) | Alzheimer's Disease (early) | Coming Soon | KBH20020 • Aβ40 | KLM0305 / KLR0092 |
Lecanemab Leqembi • Eisai / Biogen |
Beta-Amyloid (protofibrils) | Alzheimer's Disease (early) | Coming Soon | KBH20021 • Aβ42 | KLM9012 / KLR0093 |
mAb Drugs for Multiple Sclerosis (MS)
Three major approved mAb classes address MS by targeting distinct mechanisms: Natalizumab blocks α4-integrin-mediated lymphocyte trafficking across the blood-brain barrier; Ocrelizumab depletes CD20+ B cells implicated in MS pathology; and Alemtuzumab depletes CD52+ T and B lymphocytes followed by controlled immune reconstitution. Krishgen offers validated drug PK ELISA (KRIBIOLISA™ series) for each of these agents, plus their corresponding target biomarker assays — enabling simultaneous monitoring of drug concentrations and target depletion/engagement.
| Drug (Brand) | Target | Indication | Drug PK ELISA | Target ELISA (Human) | Target ELISA (Mouse/Rat) |
|---|---|---|---|---|---|
Natalizumab Tysabri • Biogen |
Alpha-4 Integrin (VLA-4) | Relapsing MS, Crohn's Disease | KBI1020 Available | KBH3900 • sα4-integrin | Contact us |
Ocrelizumab Ocrevus • Roche/Genentech |
CD20 (B cell surface) | Relapsing & Primary Progressive MS | KBI1512 Available | KBH3877 • sCD20 | Contact us |
Alemtuzumab Lemtrada • Sanofi Genzyme |
CD52 (T & B lymphocytes) | Relapsing MS (active disease) | KBI1012 Available | KBH4169 • sCD52 | Contact us |
Core biomarkers by neurological condition
Select a disease area to explore the primary research markers, their biological significance in that disease context, and available Krishgen assay catalogue numbers. All targets are available in Human, Mouse, and Rat unless otherwise noted.
Alzheimer's Disease — Amyloid, Tau, and Associated Markers
AD research centres on amyloid precursor processing (APP → Aβ40/Aβ42 via BACE1/γ-secretase), neurofibrillary tangle formation (Tau hyperphosphorylation), and synaptic loss. GFAP and NfL serve as fluid biomarkers of astrocytic activation and axonal injury. APOE genotype strongly modulates AD risk and Aβ clearance efficiency.
Parkinson's Disease — α-Synuclein, Dopaminergic Markers & Neuroprotection
PD is characterised by dopaminergic neuron loss in the substantia nigra and Lewy body accumulation (composed primarily of misfolded α-synuclein). ELISA for α-synuclein, dopamine system markers, and neuroprotective factors are core to PD research. DJ-1 (PARK7) mutations cause autosomal-recessive PD. GDNF and related neurotrophins are under active investigation as therapeutic candidates.
Multiple Sclerosis — Demyelination, BBB Integrity & Immune Activation
MS research spans demyelination markers (MBP, MOG), BBB breakdown (occludin, MMP-9, AQP-4), immune activation (lymphocyte surface antigens CD20, CD52, α4-integrin), and axonal damage (NfL, NEFH). Drug monitoring ELISA for Natalizumab, Ocrelizumab, and Alemtuzumab are available alongside their respective target biomarker assays.
ALS & Motor Neuron Disease — Protein Aggregation & Axonal Injury
ALS is defined by progressive upper and lower motor neuron degeneration. TDP-43 cytoplasmic aggregation is the pathological hallmark in ~97% of ALS cases. SOD1 mutations account for ~20% of familial ALS. NfL and NEFH are the most clinically validated fluid biomarkers for disease progression and treatment monitoring in ALS trials.
Huntington's Disease — HTT Protein, Neuroinflammation & Synaptic Markers
HD is caused by CAG repeat expansion in HTT, producing mutant huntingtin protein (mHTT) that forms nuclear inclusions and disrupts transcription, vesicle trafficking, and mitochondrial function. CSF and plasma mHTT quantification is the primary pharmacodynamic endpoint in HTT-lowering clinical trials. Neurofilament markers track neuronal loss and complement direct HTT measurement.
Neuroinflammation — Microglial Activation, Astrogliosis & CNS Cytokines
Neuroinflammation is a shared mechanism across all major neurodegenerative diseases. Activated microglia (TREM2, Iba1, CD68, CX3CR1), reactive astrocytes (GFAP, S100β), and elevated CNS cytokines (IL-6, TNF-α, IL-1β, IL-18) drive and amplify neuronal damage. These markers are increasingly used as pharmacodynamic endpoints in anti-inflammatory therapeutic strategies.
Neuroscience ELISA across 10+ species
Core neurodegeneration markers — BDNF, GFAP, Tau, Amyloid Beta, Alpha-Synuclein, NGF — are available across all major preclinical species. Contact our team for species-specific availability on any target.
Extended target list by biological system
Krishgen's neuroscience portfolio spans 200+ targets. Browse by biological system — click any block to expand the target table. All catalogue numbers link to individual product pages. Contact us if you cannot find your target.
```Neurotrophins & Growth Factors
12 targets +| Target | Human | Mouse | Rat | Other |
|---|---|---|---|---|
| BDNF | KBH1302 | KLM0013 | KLR0476 | Porcine, Canine, Sheep, Horse, Guinea Pig, Rabbit |
| NGF | KBH2102 | KLM0081 | KLR0539 | — |
| proNGF | KBH5936 | — | — | — |
| GDNF | KBH0122 | KLM0677 | KLR0351 | — |
| CDNF | KBH2889 | KLM1552 | KLR0865 | — |
| NTF4 (NT-4/5) | KBH5768 | KLM0085 | KLR0544 | — |
| CNTF | KB1022 | KLM0327 | KLR0358 | — |
| Ntn1 (Netrin-1) | KBH1277 | KLM1802 | KLR0772 | — |
| NRN1 (Neuritin) | KBH5752 | — | KLR2172 | — |
| PEDF | KBH1634 | KLM0615 | KLR0535 | — |
| NDNF | KBH21723 | KLM5986 | — | — |
| CTGF | KB1026 | KLM0688 | KLR0356 | — |
Neurotransmitter Systems
14 targets +| Target | Human | Mouse | Rat |
|---|---|---|---|
| Acetylcholinesterase (AChE) | KBH0817 | — | KLR0724 |
| Choline Acetyltransferase (ChAT) | KBH5039 | — | KLR0725 |
| Tyrosine Hydroxylase (TH) | KBH0720 | KLM1543 | KLR1316 |
| Dopamine Transporter (DAT) | KBH4006 | — | KLR0222 |
| Serotonin Transporter (SERT) | KBH3595 | — | KLR1254 |
| EAAT1 (Glutamate Transporter) | KBH20753 | KLM5493 | — |
| EAAT2 (GLT-1) | KBH20754 | KLM5494 | KLR3767 |
| Glutaminase | KBH21008 | KLM5635 | KLR2016 |
| GAD65 (GABA Synthase) | KBH3504 | — | — |
| NPY (Neuropeptide Y) | KBH1285c | KLM0704 | KLR0540 |
| Orexin A (Hypocretin-1) | KBH1296 | KLM0444 | KLR0105 |
| Galanin | KBH1332 | KLM2084 | KLR0246 |
| Neurokinin A | KBH1930 | KLM6003 | KLR2340 |
| Neuropeptide S | KBH4784 | KLM2298 | KLR2177 |
Structural, Myelin & Synaptic Markers
15 targets +| Target | Human | Mouse | Rat |
|---|---|---|---|
| Neurofilament Light (NfL / NEFL) | KBH4645 | KLM5989 | KLR1747 |
| Neurofilament Heavy (NEFH) | KBH3136 | KLM1168 | KLR0926 |
| pNF-H (Phospho-NF-H) | KBH3879 | — | — |
| MAP2 | KBH1309 | KLM5891 | KLR1772 |
| Nestin | KBH3341 | KLM1451 | KLR1174 |
| MBP (Myelin Basic Protein) | KBH5709 | KLM0548 | KLR2161 |
| MOG (Myelin Oligodendrocyte Gly.) | KBH3069 | KLM1124 | KLR0859 |
| MPZ (Myelin Protein Zero) | KBH3720 | — | KLR4130 |
| GAP43 / Neuromodulin | KBH1853 | KLM1027 | — |
| Synaptophysin (SYP) | KBH4497 | KLM2581 | KLR1496 |
| Neurogranin | KBH3883 | — | — |
| NCAM1 | KBH3986 | — | — |
| Doublecortin (DCX) | KBH4190 | KLM1744 | KLR3743 |
| Beta III Tubulin (TUBB3) | KBH6334 | — | — |
| Vimentin | KBH1673 | KLM6485 | KLR2323 |
Cellular Stress, Heat Shock & Proteostasis
8 targets +| Target | Human | Mouse | Rat | Other Species |
|---|---|---|---|---|
| HSP70 | KBH1813 | KLM1752 | KLR0522 | Canine, Porcine, Goat, Sheep, Rabbit, Guinea Pig, Chicken |
| HSP90 Alpha | KBH3002 | KLM0869 | KLR0874 | Bovine, Goat, Porcine |
| HTRA2 (Omi) | KBH2747 | — | — | — |
| Nrf2 | KBH3244 | KLM1367 | KLR1083 | — |
| IDE (Insulin-Degrading Enzyme) | KBH5471 | KLM0489 | KLR1387 | — |
| UCHL1 (PGP9.5) | KBH2328 | KLM0905 | KLR2312 | — |
| Chromogranin A | KBH1730 | KLM5357 | KLR0557 | — |
| SOD1 | KBH4502 | KLM2608 | — | — |
Selecting the Right Neuro ELISA: Assay Design, Matrix, and Species Considerations
Neurodegeneration research demands careful assay selection because many key biomarkers — Tau, Amyloid Beta, Alpha-Synuclein — exist in multiple forms (soluble, oligomeric, fibrillar) with dramatically different clinical relevance. A total Tau ELISA (KBH1333) measures all Tau isoforms, while a phospho-Tau ELISA (KBH5874) specifically captures the hyperphosphorylated species that form neurofibrillary tangles. When designing studies, clarify which form is biologically relevant before selecting an assay.
Matrix selection is particularly important in neuroscience. CSF provides the highest concentration of CNS biomarkers and is the gold-standard matrix for Tau, Amyloid Beta, and NFL. However, blood (serum/plasma) is increasingly viable — ultrasensitive detection of NfL, GFAP, and pTau in blood is now clinically relevant thanks to improvements in both assay sensitivity and sample processing. Krishgen's technical team can advise on appropriate dilution factors and pre-treatment protocols for each matrix.
For cross-species study design — transitioning from APP/PS1 or 5XFAD mouse models to human CSF — matched species kits sharing the same assay architecture minimise method variability. Krishgen offers matched Human, Mouse, and Rat kits for all core neurodegeneration targets. For preclinical models using non-human primates (NHP), contact us for Primate-specific availability.
When profiling neuroinflammation alongside neurodegeneration markers, consider pairing Krishgen's neuro-injury panel (NfL + GFAP + S100β) with our cytokine ELISA (IL-6, TNF-α, IL-1β, IFN-γ) available via the GENLISA™ range — all in Human, Mouse, and Rat with consistent plate format for streamlined multi-target workflows.
Frequently Asked Questions
Both are total Tau assays in human format. They use different antibody pairs targeting different epitopes, which may affect performance with different sample types or Tau isoform distributions. Contact our technical team for guidance on which is optimal for your specific application (CSF vs. brain homogenate vs. plasma).
NfL (KBH4645), GFAP (KBH2094), and S100β (KBH3669) perform well in serum and plasma for blood-based neurodegeneration monitoring. For Tau and Amyloid Beta, CSF remains the preferred matrix — blood concentrations are at the lower limit of standard ELISA sensitivity. Contact us for ultrasensitive format availability.
Yes. KBH20020 detects Aβ40 and KBH20021 detects Aβ42 — the antibody pairs are isoform-specific with no cross-reactivity. The Aβ42:Aβ40 ratio is more informative than either alone as a diagnostic marker. Krishgen offers matched kits for this ratio calculation.
The current catalogue covers Ocrelizumab (KBI1512). Ofatumumab and ublituximab monitoring ELISA may be available — contact info@krishgen.com with your specific requirement and we will confirm availability or custom development options.
Yes. Several targets including BDNF, NGF, GFAP, and NFL have been used with iPSC-derived neuron culture supernatants and conditioned media. We recommend testing neat and 2-fold diluted supernatant alongside known controls to establish working ranges for your specific cell model system.
Related Research Areas & Resources
Can't Find Your Neuro Target?
Krishgen manufactures 20,000+ ELISA across 10+ species. Our technical team can identify the right assay for your target, advise on sample type suitability, or initiate custom assay development for novel neurological biomarkers.
